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Background: Central giant cell lesion is a non-neoplastic proliferation, usually asymptomatic, of unknown etiology.
The purpose of this case report is to report the diagnosis and the treatment of a recurrent central giant cell lesion
in the maxilla.
Case presentation: A 31-year-old Brazilian woman presented to our Surgery Service for evaluation of a cystic
lesion in her teeth 13 and 15, although she had previously received endodontic treatment for her teeth 13 and
15 without regression of the lesion. On clinical examination, an increase and painless swelling was observed in her
right jaw. An excisional biopsy of the lesion was performed under general anesthesia; the material was sent for
pathological examination and a diagnosis compatible with central giant cell lesion was made. She presented again,
10 months after the removal of the lesion, with a recurrent lesion that surrounded her incisors, canine, and right
premolar. We suggested that she underwent treatment with intralesional corticosteroids injection. The lesion was
significantly reduced and the remainder of the lesion was enucleated. She is monitored at 3-month intervals; at
6 months postoperatively there has been no recurrence.
Conclusions: Central giant cell lesion can have a high degree of invasiveness, which increases the importance of
early diagnosis. Combination therapies can provide a favorable prognosis. Periodic monitoring is recommended,
thus avoiding the chance of a relapse.
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Central giant cell lesion (CGCL) is a benign proliferative
and asymptomatic intraosseous lesion. It is more com-
mon in females, in the third decade, without predilection
for race [1–3]. It accounts for approximately 7% of all
benign lesions in the jaw. These lesions occur more fre-
quently in the mandible than in the maxilla, and occur
more frequently on the right side than on the left side
[4, 3]. In the maxilla, the lesion may invade the maxillary
sinus floor, the orbit and/or nasal passages, which can
lead to facial asymmetry, nasal deviation, and mobility of
associated dental elements. CGCLs can be classified as
aggressive or non-aggressive. Clinical, radiographic, and* Correspondence: jeff.odontoup@gmail.com
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gressiveness and guide the treatment plan [1, 2, 5]. In
image examinations, CGCL appears as a variation of
small apical lesions to large radiolucent areas, which can
be unilocular or multilocular, with a slight opacification
within the lesion [1, 6]. On histological examination,
CGCL consists of cellular fibrous tissue with multiple
foci of hemorrhage, multinucleated giant cell aggregates
and, occasionally, trabecular bone tissue [4, 7]. The
treatment can be either conservative, with periodic corti-
costeroids infiltrations, or surgical, by enucleation or
surgical resection. Although surgical treatment tempor-
arily eliminates the lesion, clinicians need to be aware of
its aggression and morbidity and the risk of relapse [8].
The objective of this case report is to describe the treat-
ment of a recurrent CGCL in the maxilla, with thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 2 Panoramic radiograph showing a radiolucent lesion associated
with teeth 13 and 15
de Oliveira et al. Journal of Medical Case Reports  (2017) 11:74 Page 2 of 5combination of different therapies based on clinical,
radiographic, and histological characteristics.
Case presentation
A 31-year-old Brazilian woman presented to our Surgery
Department of Oral and Maxillofacial Surgery for evalu-
ation of cystic lesions in her teeth 13 and 15 and a swell-
ing on her right maxilla (Fig. 1). In her anamnesis, she
reported that she had already had endodontic treatment
for her teeth 13 and 15 without regression of the lesion.
Her teeth 14 and 24 had been previously removed for
orthodontic treatment. A radiographic and computed
tomography (CT) examination showed a radiolucent
lesion, diffuse, of approximately 20 mm, involving the
teeth 13 and 15. The initial diagnosis was inflammatory
periapical cyst (Fig. 2).
She underwent preoperative laboratory tests and an
excisional biopsy of the lesion was undertaken under
general anesthesia. The choice of the use general
anesthesia was due to the size of the lesion and possibil-
ity of enucleation without removal of the teeth involved.
The collected material was sent for pathological examin-
ation. The result was compatible with CGCL (Figs. 3
and 4), which differed from our diagnostic hypothesis.
After the definitive diagnosis, she was advised to carry
out regular monitoring because of the risk of recurrence.
She self-monitored for a period of 10 months; she then
presented again with a complaint of swelling on the site,
but without the presence of pain. A new CT scan was re-
quested and indicated recurrence of the lesion, which
now involved the region’s incisor, canine, and premolar
(Fig. 5). New laboratory tests were carried out: alkaline
phosphatase, calcium, phosphorus, and parathyroid hor-
mone (PTH). We ruled out the possibility of the lesion
being compatible with Brown tumor of hyperparathyr-
oidism. A possible loss of the four dental elements
involved was not ruled out.
We proposed new treatment with intralesional cortico-
steroid injections to our patient in an attempt to reduce
the lesion for a future enucleation. She was given a drug
application schedule: nine applications in the affectedFig. 1 Panoramic radiograph pre-treatment endodonticregions with intervals of 15 days between applications.
Infiltrations were composed of: Triancil® (triamcinolone
hexacetonide) + Xylestesin® (lidocaine hydrochloride;
Fig. 6). On average, 1.5 ml of the solution per session
was applied at different points. After 5 months, there
was a reduction in the lesion. New imaging tests showed
that her tooth 16 had external root reabsorption and we
decided to carry out an extraction of this tooth during
the enucleation of the remaining lesion. We also found
the formation of a septum in the damaged area, indicat-
ing bone formation (Figs. 7 and 8).
The enucleation of the remaining lesion was per-
formed under general anesthesia. During surgery we
removed tooth 16 as planned. Tooth 15 had no sup-
port because the buccal bone plate had been compro-
mised, so we decided to extract it during surgery
(Fig. 9). A radiograph was performed 7 days postoper-
atively (Fig. 10).
At 6 months postoperatively, she is on a quarterly
follow-up, without recurrence of the lesion (Figs. 11
and 12). A bone reconstruction of the region is planned
for 1 year postoperatively.Fig. 3 Intra-bone dense connective tissue with oval spindle cells
and giant cells, indicating a fibroma (granuloma) central giant cell.
Hematoxylin and eosin 40×
Fig. 4 Microscopical details of the biopsied fragment where
multinucleated giant cells (arrows) surrounded by intense connective
tissue and some spindle mesenchymal cells, characterizing the classical
histopathological frame of central giant cell lesions, can be found
Fig. 6 Combination of Triancil® (triamcinolone hexacetonide) and
Xylestesin® (lidocaine hydrochloride) used in infiltrations
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CGCL is a non-neoplastic proliferation with variable
clinical behavior and unknown etiology. However, multi-
nucleated giant cells in this type of lesion are concen-
trated in areas of hemorrhage and adjacent to blood
vessels, suggesting that CGCL represents a phagocytic
response to the hemorrhage, indicating that factors such
as trauma and extractions may be related to this path-
ology. CGCL accounts for approximately 7% of all
benign lesions in the maxilla. These lesions occur more
frequently in the mandible than in the maxilla with more
involvement in the right side [4, 2, 5, 9, 10]. CGCL is
more common in females, with a ratio 2:1 [7]. This
lesion can occur at all ages, but most cases were
diagnosed between the second and third decade of life
[1, 9, 11].
CGCL can be aggressive and non-aggressive. The non-
aggressive form is characterized by slow growth, is
typically asymptomatic, and does not pierce cortical
bone or induce root reabsorption; it has a low recur-
rence rate. The aggressive form is characterized by epi-
sodes of nonspecific pain, rapid growth, large lesions
(>5 cm), paresthesia, root reabsorption, cortical perfor-
ation, a high rate of post-treatment enucleation recur-
rence and often produces edema [12].Fig. 5 Panoramic image of computed tomography scan
showing recurrenceOn radiographic examination, CGCL varies from small
apical lesions to large lesions involving multilocular radio-
lucent areas of maxilla [1]. The presence of a thin opacifica-
tion within the lesion is the most significant radiographic
signal associated with CGCL [8]. Its appearance is usually
consistent with a unilocular or multilocular radiolucency,
well or poorly defined, plus a varied expansion and de-
struction of the cortical plate. This pattern is not pathog-
nomonic radiographically and can be confused with many
other injuries in the maxilla and mandible [13]. CT is
an excellent imaging examination to demonstrate bone
destruction or bone thinning. CGCL located at the
apical side or at the roots of teeth can be easily con-
fused with odontogenic inflammatory lesions such as
inflammatory periapical cysts or radicular cysts. The
common occurrence of these lesions leads the dentist
to a definitive diagnosis without major additional tests.Fig. 7 Panoramic image of computed tomography scan showing
formation of a bony septum indicating new bone formation
Fig. 8 Axial image from computed tomography scan showing lesion
divided by bony septum
Fig. 10 Panoramic radiograph 7 days postoperatively
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when there is associated periapical radiolucency [14].
On histological examination, CGCL are represented
by multinucleated giant cells in a prominent fibrous
stroma. Osteoclasts have irregular distribution and are
associated with areas of hemorrhage. Structurally the
proliferative cells include spindle-shaped fibroblasts,
myofibroblasts, and mononuclear inflammatory cells
[15]. Foci of hemorrhage with release of hemosiderin
pigment are often seen. Immunohistochemical studies
in cases of CGCL have helped establish the lineage
and pattern of these cells; however, they cannot pre-
dict the aggressiveness of the lesion. The final diagno-
sis possibly rests on the histopathological data
because the clinical and radiographic features are
nonspecific [13, 7, 11]. The differential diagnosis in-
cludes aneurysmal bone cyst, giant cell tumor, and
brown tumor of hyperparathyroidism [15].Fig. 9 Transoperative image of enucleation of the lesion under
general anesthesia, with removal of teeth 15 and 16The traditional treatment of CGCL is surgical excision,
enucleation, or en bloc resection. This choice depends on fac-
tors such as aggressive and non-aggressive form, location,
size, and radiographic appearance. Other treatments include
radiation, systemic injections of calcitonin, interferon, and
intralesional injections with corticosteroids [15]. The ap-
proach is calcitocina enhances and inhibits osteoclast
activity such as surgery and application of calcitonin [16].
However, due to their great discomfort and relatively long
treatment time, this treatment is not well accepted by all
patients [2]. Interferon-alpha is useful in managing aggres-
sive CGCL due to its anti-angiogenic effects [17].
Intralesional injections with corticosteroids are increas-
ingly used clinically, and some studies show excellent
results. They can be considered a first treatment option.
With a less invasive approach, these injections can be used
individually or in combination with other therapies, such
as surgery and calcitonin [1, 10]. Intralesional injection is
preferred than systemic injection, because in first one
it is possible to achives a high drug concentration in
tissue [12]. Systemic complications associated with
administration of corticosteroids are seldom reported [1].Fig. 11 Intraoral photograph at 6 months postoperatively
Fig. 12 Panoramic image from computed tomography scan
showing opacification in the damaged area, indicating bone repair
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radical approach. The management of these lesions
depends on clinical and radiographic findings. In gen-
eral, the enucleation of well-defined and localized lesions
is associated with a low recurrence rate. In extensive
lesions, based on imaging tests, where there has been
cortical drilling, a more radical excision is mandatory
[17]. Enucleation remains the most common treatment
modality for CGCL; however, a rate of 24% recurrence
was reported in non-aggressive lesions, so the preference
for associations with other modalities is common [3]. In
some cases, loss of teeth and loss of erupted and non
erupted teeh are inevitable, as well root reabsorptions in
the affected area [15]. Periodic monitoring with radio-
graphs and clinical evaluations should be conducted to
prevent recurrence.
Conclusions
Given the above, the correct diagnosis of CGCL and its
degree of aggressiveness is achieved through an analysis
of clinical, radiographic, and pathological examinations.
The treatment plan may vary from noninvasive therap-
ies, such as medication, to surgical approach, wherein
enucleation is proposed. There is also the possibility of a
combination of techniques. The combination of two
different therapies can be a good solution, since in
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